PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Cancer Chemother Pharmacol. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
Cancer Chemother Pharmacol. 2010 October; 66(5): 973–980.
Published online 2010 February 2. doi: 10.1007/s00280-010-1250-z

Table 3

Incidence toxicity by dose level. Events that are unlikely to be related to treatment were excluded.

Number of patients experiencing toxicity (all grades |grade 3 or 4)
Dose Level
−1(n=6)
Dose Level
1(n=4)
Dose Level
2(n=3)
Dose Level
3(n=6)
Dose Level
4(n=4)
Total
Nausea4 1 3 1 204 2 3 1 16 5
Diarrhea4030104 2 2014 2
Vomiting4 1 1 1 104 1 3 1 13 4
Abdominal
pain or cramp
404 1 00203013 1
Fatigue5 1 * 20103 1 * 2013 2
Lightheaded/
Dizziness
201010300070
Flushing200010100040
Hiccups001020100040
Dehydration200000101040
Dyspnea100000201040
Hypoxia001 1 * 002 1 003 2
Cough001010001030
Anorexia101000001030
Chills000000300030
Diaphoresis100000200030
Neuropathy
sensory,
101010000030
Headache100010100030
Flatulence001000002030
Leukocytes103 2 002 2 3 3 9 7
Neutrophils2 1 3 2 * 1 1 2 1 3 3 11 8
Hemoglobin00200 0 003 1 5 1
Platelets001 1 00101 1 * 3 2
*DLT